Picture loading failed.

Anti-KLKB1 therapeutic antibody (Pre-made Lanadelumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Lanadelumab (INN; trade name Takhzyro) is a human monoclonal antibody (class IgG1 kappa)that targets plasma kallikrein (pKal) in order to promote prevention of angioedema in patients with hereditary angioedema. Lanadelumab, was approved in the United States as the first monoclonal antibody indicated for prophylactic treatment to prevent hereditary angioedema (HAE) attacks. Takhzyro is the first treatment for hereditary angioedema (HEA) prevention made by using cells within a lab, not human plasma.[8] The US Food and Drug Administration approved the use of lanadelumab on 23 August 2018 for patients that are 12 years and older and suffering from either type I or type II hereditary angioedema (HEA). Administration of the medication is done through 1 subcutaneous injection at a dose of 300 milligrams every 2 weeks (every 4-week dosing can be considered in specific patients).

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-294-1mg 1mg 3090
GMP-Bios-ab-294-10mg 10mg 21890
GMP-Bios-ab-294-100mg 100mg 148000
GMP-Bios-ab-294-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-KLKB1 therapeutic antibody (Pre-made Lanadelumab biosimilar,Whole mAb)
INN Name Lanadelumab
TargetKLKB1
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusNFD
100% SI Structure4pub:HL/4ogy:HL:MN/4ogx:HL
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesDyax;Shire;Takeda
Conditions ApprovedHereditary angioedema
Conditions Activena
Conditions DiscontinuedDiabetic macular oedema
Development Techna